PENTRAXIN 3 AS A NEW CARDIOVASCULAR MARKER IN ADRENAL ADENOMAS

Objective: Pentraxin 3 (PTX3) is an acute-phase glycoprotein, which is increased in patients with cardiovascular disease (CVD) and considered as a predictor of CVD in the general population. Both functional and nonfunctional adrenal tumors are associated with a higher risk of cardiovascular events and mortality. We aimed to investigate plasma PTX3 levels in patients with functioning and nonfunctioning adrenal tumors and determine its relationship with cardiovascular risk factors. Methods: Twenty-one patients with functional adrenal tumors (11 pheochromocytomas, 9 Cushing syndrome, and 1 primary hyperaldosteronism), 28 patients with nonfunctional adrenal incidentalomas, and 40 healthy controls were enrolled in the study. Serum PTX3 levels were measured using a human PTX3 enzyme-linked immunosorbent assay. Results: PTX3 concentrations were significantly higher in the adrenal tumor group compared with the control group (3,001.64 +/- 374.64 pg/mL vs. 1,173.59 +/- 168.89 pg/mL; P<.001). PTX3 concentrations were positively correlated with carotid intima media thickness (CIMT) (r(2), 0.464; P<. 001), high-sensitivity C-reactive protein (hsCRP) (r(2), 0.551; P<. 001), diastolic blood pressure (r(2), 0.334; P =.003), systolic blood pressure (r(2), 0.312; P =.006), and urinary metanephrine concentrations (r(2), 0.320; P =.041). Serum PTX3 concentrations in patients with functional adrenal tumors and comorbidities including hypertension, diabetes mellitus, or CVD were higher than in those without comorbidities (3,654.54 +/- 447 pg/mL vs. 1,026.96 +/- 447.97 pg/mL; P =.008). Conclusion: We found that serum PTX3 concentrations increased in both functional and nonfunctional adrenal tumors. PTX3 levels were correlated with cardiovascular risk factors such as CIMT, hsCRP, and blood pressure.